|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
|
31706682 |
2020 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Following drug resistance in patients with lung cancer treated by EGFR TKIs, a biopsy is required to obtain sufficient cancer tissue for T790M detection in order to select potential beneficiaries suitable for third-generation EGFR TKIs, such as osimertinib.
|
31407509 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We reviewed all patients with T790M-positive NSCLC and acquired resistance to initial EGFR-TKIs who were administered osimertinib between March 2016 and January 2018 at the Tokyo Metropolitan Cancer and Infectious Diseases Center in Komagome Hospital, Japan.
|
31372272 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
|
30015588 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This approach detects mutations as subtle as the drug-resistance-conferring cancer mutation EGFR T790M (a single C → T substitution) with an estimated specificity of 99.99999%, surpassing even the leading PCR-based methods and enabling detection of 1 mutant molecule in a background of at least 1 million wild-type molecules.
|
30125495 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
To assess the biological implications of <i>RET</i> fusions in an <i>EGFR</i>-mutant cancer, we expressed CCDC6-RET in PC9 (<i>EGFR</i> del19) and MGH134 (<i>EGFR</i> L858R/T790M) cells and found that CCDC6-RET was sufficient to confer resistance to EGFR tyrosine kinase inhibitors (TKI).
|
30257958 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.
|
29183267 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M mutations disappeared from cancer cells in the pleural effusion after a break from the treatment drug and cytotoxic agent administration.
|
30145590 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This could further help avoid unnecessary tumor biopsies for T790M mutation testing.<i>Clin Cancer Res; 24(12); 2944-50.©2018 AACR</i>.
|
29535126 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Liquid biopsy offers a potential alternative to tissue biopsy for detection of genetic alterations in cancer, and it has been introduced into clinical practice to detect the tyrosine kinase inhibitor (TKI) resistance-conferring T790M mutation of epidermal growth factor receptor (EGFR) in patients with non-small-cell lung cancer (NSCLC).
|
30289575 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Indeed, the use of plasma testing to screen for epidermal growth factor receptor (<i>EGFR</i>) T790M mutant positive non-small cell lung cancer (NSCLC) patients eligible for treatment with third-generation EGFR inhibitors was recently approved by the U.S. Food and Drug Administration and is incorporated into the most recent version of the National Comprehensive Cancer Center guidelines as an alternative to tissue biopsy.
|
29184671 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In two patients, the ctDNA dynamics suggested the presence of cancer cell populations only with the T790M mutation.
|
26678713 |
2016 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The objective responses were observed in NSCLC patients with EGFR T790M mutation.Mol Cancer Ther; 15(11); 2586-97.©2016 AACR.
|
27573423 |
2016 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790M) in NSCLC with in situ fluorescence imaging, which can be directed to determine various treatment options in patients with cancer.
|
20805561 |
2010 |
|
rs121434569
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |